Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Summary

This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.

Timeline

Start

2021-03-17

Primary completion

2024-05-17

Completion

2024-05-17

Publications

• Cao CD, McCorkle JR, Yan D, Esfahani HS, Jayswal R, Piecoro D, Li N, Baldwin LA, Miller RW, Desimone CP, Dietrich CS, Ueland FR, Kolesar JM. A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer. Cancers (Basel). 2026 Feb 14;18(4):626. doi: 10.3390/cancers18040626.

Drugs

Indications